Tick-borne encephalitis vaccination (FSME-IMMUN, Belgium)

FSME-IMMUN vaccine (0.5 ml) is indicated for the active (preventive) tick-borne encephalitis immunization of people over 16 years of age.

FSME-IMMUN Junior vaccine (0.25 ml) is indicated for the active (preventive) tick-borne encephalitis immunization of children from 1 to 15 years of age.

Manufactured by: Pfizer Manufacturing Belgium NV.

1 dose of FSME-IMMUN Junior vaccine (0.25 ml) includes the virus of tick-borne encephalitis (Neudörfl strain), 1.2–1.2 mcg:

• 1 - adsorbed on aluminium hydroxide, hydrated (0.17 mg Al3+);
• 2 - grown on fibroblast culture of chicken embryo cells (CEF cells).

1 dose of FSME-IMMUN vaccine (0.5 ml) includes the virus of tick-borne encephalitis (Neudörfl strain), 1.2–2.4 mcg:

• 1 - adsorbed on aluminium hydroxide, hydrated (0.35 mg Al3+);
• 2 - grown on fibroblast culture of chicken embryo cells (CEF cells).

The primary vaccination schedule is the same for all individuals and consists of three vaccinations with the FSME-IMMUN vaccine (0.5 ml) for people over 16 years of age or the FSME-IMMUN Junior (0.25 ml) for children from 1 to 15 years of age.

Routine and emergency vaccination schedules are different. The scheme is prescribed by the doctor who sent a person for the vaccination. Emergency vaccination should be started as soon as possible after the exposure to the tick.

Vaccine administration method: intramuscularly

If necessary, the vaccine can be administered subcutaneously (for people with blood clotting disorders or anticoagulant preventive care).